Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2016, vol. 25, nr 4, July-August, p. 655–663

doi: 10.17219/acem/58785

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Diabetic Patients with an Acute Myocardial Infarction in Terms of Risk Factors and Comorbidities Management: Characteristics of the Highest-Risk Individuals

Józefa Dąbek1,A,E,F, Mariusz Bałys1,A,B,C,D, Michał Majewski1,D,E, Zbigniew T. Gąsior1,F

1 Chair and Department of Cardiology, School of Health Sciences, Medical University of Silesia, Katowice, Poland


Background. Patients with diabetes mellitus (DM) and acute myocardial infarction (AMI) are heterogeneous individuals with different clinical status compared to patients without DM.
Objectives. The aim of this study was to analyze the group of diabetic patients with ST-segment elevation MI (STEMI) or non-ST-segment elevation infarction (NSTEMI) including risk factors, medical history, laboratory findings, advancement of coronary vessel atherosclerosis, and diagnostics and therapeutic modalities performed. A comparison of groups according to the type of MI was also made.
Material and Methods. The study involved all (n = 130) patients with DM and AMI, hospitalized in the Department of Cardiology, Medical University of Silesia, Katowice, in 2012. Clinical presentation, medical history, laboratory tests, imaging studies and additional tests as well as treatment management data were collected. Statistical analysis of the data obtained was performed using STATISTICA® software. Coronary angiography was performed in 120 subjects (92.3%).
Results. NSTEMI almost doubled STEMI occurrence in the study group (65.4% vs. 34.6%). Left main disease (LMD) was more often diagnosed in the NSTEMI subgroup of patients (14.1% vs. 6.7%). There were no significant differences between the compared groups as far as clinical presentation and comorbidities are concerned; more frequent previous PCI in NSTEMI patients was noticed, however (37.7% vs. 17.8%; p = 0.0195). The STEMI subgroup was characterized by higher leukocytosis (13.2 vs. 10.0 × 103/μL; p < 0.001) and serum glucose concentration (217 vs. 182 mg%; p = 0.001); they were also treated with invasive methods more frequently (95.5% vs. 75%; p < 0.001) and the left anterior descending artery was delivered with stents more frequently (63.3% vs. 48.7%; p = 0.0426).
Conclusion. Patients with DM and AMI are burdened with metabolic disorders and numerous risk factors. They require aggressive diagnostics and therapy including new revascularization techniques and optimal medical treatment. Regardless of the type of AMI (STEMI or NSTEMI), the study group was homogeneous in terms of complaints, comorbidities and metabolic profile.

Key words

treatment, diabetes mellitus, acute myocardial infarction

References (30)

  1. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Sousa Uva M, Storey RF, Wijns W, Zahger D: ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011, 32, 2999–3054.
  2. Balasubramaniam K, Viswanathan GN, Marshall SM, Zaman AG: Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: A review of antiplatelet therapy. Cardiol Res Pract 2012, 2012, 909154.
  3. Grant PJ: Diabetes mellitus as a prothrombotic condition. J Intern Med 2007, 262, 157–172.
  4. Zhu Z, Zhou H, Yu X, Chen L, Zhang H, Ren S, Wu Y, Luo D: Potential regulatory role of calsequestrin in platelet Ca(2+) homeostasis and its association with platelet hyperactivity in diabetes mellitus. J Thromb Haemost 2012, 10, 116–124.
  5. Ferreiro JL, Angiolillo DJ: Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 2011, 22, 123, 798–813.
  6. Tang WH, Stitham J, Gleim S, Di Febbo C, Porreca E, Fava C, Tacconelli S, Capone M, Evangelista V, Levantesi G, Wen L, Martin K, Minuz P, Rade J, Patrignani P, Hwa J: Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane. J Clin Invest 2011, 121, 4462–4476.
  7. Watala C, Golański J, Boncler MA, Pietrucha T, Gwoździński K: Membrane lipid fluidity of blood platelets: A common denominator that underlies the opposing actions of various agents that affect platelet activation in whole blood. Platelets 1998, 9, 315–327.
  8. Gawlowski T, Stratmann B, Ruetter R, Buenting CE, Menart B, Weiss J, Vlassara H, Koschinsky T, Tschoepe D: Advanced glycation end products strongly activate platelets. Eur J Nutr 2009, 48, 475–481.
  9. Poloński L, Gasior M, Gierlotka M, Kalarus Z, Cieśliński A, Dubiel JS, Gil RJ, Ruzyłło W, Trusz-Gluza M, Zembala M, Opolski G: Polish Registry of Acute Coronary Syndromes (PL-ACS). Characteristics, treatments and outcomes of patients with acute coronary syndromes in Poland. Kardiol Pol 2007, 65, 861–872.
  10. Norhammar A, Lagerqvist B, Saleh N: Long-term mortality after PCI in patients with diabetes mellitus: Results from the Swedish Coronary Angiography and Angioplasty Registry. EuroIntervention 2010, 5, 891–897.
  11. Lingman M, Herlitz J, Bergfeldt L, Karlsson T, Caidahl K, Hartford M: Acute coronary syndromes – the prognostic impact of hypertension, diabetes and its combination on long-term outcome. Int J Cardiol 2009, 11, 137, 29–36.
  12. Bartnik M, Rydén L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, Standl E, Soler-Soler J, Ohrvik J: Euro Heart Survey Investigators. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004, 25, 1880–1890.
  13. Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Rydén L: Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 2004, 25, 1990–1997.
  14. Bakhai A, Collinson J, Flather MD, de Arenaza DP, Shibata MC, Wang D, Adgey JA: KAA Fox for the PRAIS-UK Investigators. Diabetic patients with acute coronary syndromes in the UK: high risk and under treated. Results from the prospective registry of acute ischaemic syndromes in the UK (PRAIS-UK). Int J Cardiol 2005, 8, 100, 79–84.
  15. Lingman M, Herlitz J, Bergfeldt L, Karlsson T, Caidahl K, Hartford M: Acute coronary syndromes – the prognostic impact of hypertension, diabetes and its combination on long-term outcome. Int J Cardiol 2009, 11, 137, 29–36.
  16. Jax TW, Peters AJ, Plehn G, Schoebel FC: Relevance of hemostatic risk factors on coronary morphology in patients with diabetes mellitus type 2. Cardiovasc Diabetol 2009, 6, 8, 24.
  17. Marso SP, Mercado N, Maehara A, Weisz G, Mintz GS, McPherson J, Schiele F, Dudek D, Fahy M, Xu K, Lansky A, Templin B, Zhang Z, de Bruyne B, Serruys PW, Stone GW: Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes. JACC Cardiovasc Imaging 2012, 5, Suppl 3, 42–52.
  18. Kuliczkowski W, Gąsior M, Pres D, Kaczmarski J, Greif M, Łaszewska A, Szewczyk M, Hawranek M, Tajstra M, Żegleń S, Poloński L, Serebruany V: Effect of glycemic control on response to antiplatelet therapy in patients with diabetes mellitus and ST-segment elevation myocardial infarction. Am J Cardiol 2012, 1, 110, 331–336.
  19. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D: Guidelines on myocardial revascularization. Eur Heart J 2010, 31, 2501–2555.
  20. Lee MS, Jurewitz D, Zimmer R, Pessegueiro A, Bhatia R, Currier J, Yeatman L, Tobis JM: Impact of diabetes and acute coronary syndrome on survival in patients treated with drug-eluting stents. Catheter Cardiovasc Interv 2008, 1, 72, 909–914.
  21. Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Mazzone T, Raskin P: Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Anesthesiology 2008, 109, 14–24.
  22. [No authors listed]. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 12, 352, 837–853.
  23. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hébert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ: Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009, 26, 360, 1283–1297.
  24. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, Grobbee DE, Kengne AP, Marre M, Heller S: Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010, 7, 363, 1410–1418.
  25. Monteiro S, Monteiro P, Gonçalves F, Freitas M, Providência LA: Hyperglycaemia at admission in acute coronary syndrome patients: prognostic value in diabetics and non-diabetics. Eur J Cardiovasc Prev Rehabil 2010, 17, 155–159.
  26. Steg PG, James SK, Atar D: ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012, 33, 2569–2619.
  27. Kushner FG, Hand M, Smith SC Jr: 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/ SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009, 1, 54, 2205–2241.
  28. Rydén L, Grant PJ, Anker SD: ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013, 34, 3035–3087.
  29. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000, 12, 321, 405–412.
  30. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N: Association of hemoglobin A1c with cardiovascular disease and mortality in adults: The European prospective investigation into cancer in Norfolk. Ann Intern Med 2004, 21, 141, 413–420.